Claims for Patent: 8,129,166

Summary for Patent: 8,129,166

Title:	Immunogenic minicells and methods of use
Abstract:	The disclosed invention relates to immunogenic minicells cells (anucleated) and their use to induce an immune response from a subject.
Inventor(s):	Sabbadini; Roger A. (Lakeside, CA), Berkley; Neil (San Diego, CA), Surber; Mark (San Diego, CA)
Assignee:	Vaxiion Therapeutics, Inc. (San Diego, CA)
Application Number:	12/133,308
Patent Claims:	1. A fully intact eubacterial minicell for use in generating an immunogenic response in an animal, comprising a plasmid having an open reading frame encoding a bacterial antigen of interest, and a eukaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in said animal. 2. The minicell of claim 1, wherein said eukaryotic expression sequence comprises a CMV promoter. 3. The minicell of claim 1, wherein said eukaryotic expression sequence comprises a stress-inducible promoter. 4. The minicell of claim 1, wherein said open reading frame is from the genome of a bacterium. 5. The minicell of claim 4, wherein said bacterium is a pathogen. 6. The minicell of claim 5, wherein said bacterium is selected from the group consisting of Bacillus anthracis, Escherichia coli, Salmonella spp., Chlamydia, Mycobacterium tuberculosis, Borrelia burgdorfei and Shigella spp. 7. The minicell of claim 1, further comprising a prokaryotic expression sequence operably linked to said open reading frame, such that said antigen of interest is expressed in the minicell and the animal. 8. The minicell of claim 7, wherein said antigen of interest expressed in the minicell is displayed on the surface of the minicell.

Details for Patent 8,129,166

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Emergent Biodefense Operations Lansing Llc	BIOTHRAX	anthrax vaccine adsorbed	Injection	103821	11/12/1998		2021-05-24